The generative AI market in drug discovery is expanding rapidly, expected to grow from $0.33 billion in 2026 to $0.86 billion by 2030 with a 27% CAGR. Growth is fueled by rising drug development costs, advances in AI technologies like deep learning, and increased biological data availability. Key trends include AI-driven molecule generation and faster early-stage drug development, with major companies like Bayer, NVIDIA, and Merck leading innovations. The market is also benefiting from more clinical trials and strategic acquisitions, indicating a transformative impact on pharmaceutical R&D and personalized medicine.
Samsung reported a record 5.7 times year-over-year growth in memory revenue, now making up 70% of its total revenue. This growth was achieved without heavy reliance on Nvidia, as no single customer accounts for more than 10% of Samsung's revenue. Loo...
China is focusing its resources on developing artificial intelligence (AI) rather than real estate, aiming for self-sufficiency without surpassing the US in AI technology. Despite significant private sector investment in the US—around 23 times more t...
JonesTrading strategist Mike O'Rourke highlights that the upcoming wave of AI IPOs, including Anthropic, SpaceX, and OpenAI, depends more on what investors are willing to pay than on the companies' fundamentals. Anthropic targets a 40-50x revenue mul...
Nvidia will provide up to $105 billion in financing for a massive AI data center in Ohio, leased by OpenAI under a 20-year deal. The facility will offer about eight gigawatts of computing power, supporting AI products like ChatGPT and creating thousa...
AI-infrastructure stocks like Coherent, Applied Materials, and Sandisk are experiencing robust revenue growth and optimistic future demand, indicating a genuine AI buildout rather than a market bubble. Upcoming earnings reports from Nvidia and Micron...
